TOPAS Simulation of the Mevion S250 compact proton therapy unit

&NA; As proton therapy becomes increasingly popular, so does the need for Monte Carlo simulation studies involving accurate beam line modeling of proton treatment units. In this study, the 24 beam configurations of the Mevion S250 proton therapy system installed recently at our institution were modeled using the TOolkit for PArticle Simulation (TOPAS) code. Pristine Bragg peak, spread out Bragg peak (SOBP), and lateral beam profile dose distributions were simulated and matched to the measurements taken during commissioning of the unit. Differences in the range for all Percent Depth Dose (PDD) curves between measured and simulated data agreed to within 0.1 cm. For SOBP scans, the SOBP widths all agreed to within 0.3 cm. With regards to lateral beam profile comparisons between the measured and simulated data, the penumbras differed by less than 1 mm and the flatness differed by less than 1% in nearly all cases. This study shows that Monte Carlo simulation studies involving the Mevion S250 proton therapy unit can be a viable tool in commissioning and verification of the proton treatment planning system.

[1]  H Paganetti,et al.  Accurate Monte Carlo simulations for nozzle design, commissioning and quality assurance for a proton radiation therapy facility. , 2004, Medical physics.

[2]  H. Paganetti.  Range uncertainties in proton therapy and the role of Monte Carlo simulations , 2012, Physics in medicine and biology.

[3]  R. Mohan,et al.  The risk of developing a second cancer after receiving craniospinal proton irradiation , 2009, Physics in medicine and biology.

[4]  Roelf Slopsema,et al.  Sensitivities in the production of spread-out Bragg peak dose distributions by passive scattering with beam current modulation. , 2007, Medical physics.

[5]  Z. Tochner,et al.  Proton Beam Irradiation in Pediatric Oncology: An Overview , 2005, Journal of pediatric hematology/oncology.

[6]  Commissioning and initial experience with the first clinical gantry‐mounted proton therapy system , 2016, Journal of applied clinical medical physics.

[7]  Alfred R. Smith,et al.  Initial beam size study for passive scatter proton therapy. I. Monte Carlo verification. , 2007, Medical physics.

[8]  A. Wroe,et al.  Evaluation of the dosimetric properties of a diode detector for small field proton radiosurgery , 2015, Journal of applied clinical medical physics.

[9]  W. Newhauser,et al.  Virtual commissioning of a treatment planning system for proton therapy of ocular cancers. , 2005, Radiation protection dosimetry.

[10]  R. Wilson.  Radiological use of fast protons. , 1946, Radiology.

[11]  Alfred R. Smith,et al.  Initial beam size study for passive scatter proton therapy. II. Changes in delivered depth dose profiles. , 2007, Medical physics.

[12]  Wayne D Newhauser,et al.  The physics of proton therapy , 2015, Physics in medicine and biology.

[13]  Harald Paganetti,et al.  Uncertainties and correction methods when modeling passive scattering proton therapy treatment heads with Monte Carlo , 2011, Physics in medicine and biology.

[14]  H. Kooy,et al.  Proton radiation in the management of localized cancer , 2010, Expert review of medical devices.

[15]  H Paganetti,et al.  Experimental validation of the TOPAS Monte Carlo system for passive scattering proton therapy. , 2013, Medical physics.

[16]  Joao Seco,et al.  Automated Monte Carlo Simulation of Proton Therapy Treatment Plans , 2016, Technology in cancer research & treatment.

[17]  Katia Parodi,et al.  Clinical implementation of full Monte Carlo dose calculation in proton beam therapy , 2008, Physics in medicine and biology.

[18]  R. Mohan,et al.  Analysis of the track- and dose-averaged LET and LET spectra in proton therapy using the geant4 Monte Carlo code. , 2015, Medical physics.

[19]  H Paganetti,et al.  TOPAS: an innovative proton Monte Carlo platform for research and clinical applications. , 2012, Medical physics.

[20]  Marco Durante,et al.  Assessing the risk of second malignancies after modern radiotherapy , 2011, Nature Reviews Cancer.